source
- City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt diseaseCity Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…
- Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidatesCavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round. The capital is intended to move its first t…